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Abstract
It is well established that delaying the administration of effective antimicrobials for the treatment of serious infections has a signiﬁcant
impact on patient outcomes. In this atmosphere of urgency, decision-making regarding therapy is further complicated by the current
high rates of drug resistance among important pathogens, such as Staphylococcus aureus. To improve treatment outcomes, decrease the
risk of mortality and reduce hospital costs, physicians should always administer the most appropriate antimicrobial for the given sce-
nario. When a staphylococcal infection is suspected but the resistance phenotype is not known, agents that are effective against methi-
cillin-susceptible S. aureus and methicillin-resistant S. aureus provide optimal empirical coverage. However, the number of such empirical
monotherapeutic options is limited. Daptomycin has proven clinical efﬁcacy as compared with comparator agents in Gram-positive
infections, and could be considered an appropriate therapy for the treatment of infections caused by either methicillin-susceptible
S. aureus or methicillin-resistant S. aureus.
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Introduction
Serious Gram-positive infections are a signiﬁcant problem
faced by physicians and can be difﬁcult to diagnose and treat.
The increasing incidence of Gram-positive bacteria with
decreased susceptibility to many frequently used antimicrobi-
als makes treating these infections even more problematic
[1,2]. Optimal outcomes are achieved in patients for whom
antimicrobial therapy is appropriate and adequate [3,4].
Adequate therapy can be deﬁned as therapy to which the
causative pathogen is susceptible, as determined in vitro on
the basis of clinical breakpoints [5,6]. Appropriate therapy is
an adequate therapy that is additionally deemed to be rela-
tively favourable with respect to other considerations,
including head-to-head clinical trial comparisons with alterna-
tive therapies, antimicrobial penetration into tissues, safety
and tolerability, and cost-effectiveness [5,6]. Furthermore, an
appropriate therapy is given at the correct dose and interval.
The impact of inadequate antimicrobial therapy on patient
outcomes is signiﬁcant, increasing the risk of hospital
mortality by up to two-fold in serious infections as compared
with adequate therapy [5,7–10]. Of further consequence is
the ﬁnding that the use of an inappropriate or suboptimal
empirical therapy for serious infections, including those
caused by Staphylococcus aureus, is also associated with
increased mortality and duration of hospitalization [3,4,11].
To enable the administration of adequate antimicrobial
regimens to patients, clinicians ideally require the results of
bacteriological culture and susceptibility tests. Unfortunately,
in current practice, obtaining such results may take 2–3 days.
To avoid delays in therapy, which can have signiﬁcant
consequences for treatment outcomes in serious infections
[12], clinicians regularly make decisions on empirical therapy
immediately on presentation, without the beneﬁt of laboratory
results, thereby making educated guesses as to the causative
pathogens and their resistance phenotypes. This review will
discuss two case studies exploring the choice of appropriate
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empirical therapy for serious infections caused by Gram-posi-
tive organisms with unknown methicillin susceptibility.
The Empirical Dilemma
What is the impact of choosing inappropriate therapy?
In the USA [13] and a number of European countries
(including the UK, Italy and Greece) [1], infections caused
by methicillin-resistant S. aureus (MRSA) can account for up
to 50% of all nosocomial S. aureus infections. At a time
when MRSA rates are high or increasing in many countries
[1], the traditional options for treating suspected S. aureus
infections create an empirical dilemma: should the clinician
select an agent that is most appropriate against methicillin-
susceptible S. aureus (MSSA) but not MRSA, or one that is
most appropriate against MRSA but not MSSA? Choosing
vancomycin as the empirical therapy in all cases of sus-
pected S. aureus infections may not be the most appropriate
option, despite its adequacy according to in vitro susceptibil-
ity data [14]. For example, several recent studies have indi-
cated that vancomycin may be inferior to b-lactams for the
empirical treatment of MSSA infections. For MSSA bactera-
emia, vancomycin was associated with signiﬁcantly higher
rates of treatment failure [15–17] and infection-related mor-
tality than treatment with b-lactams [16,17]. Similarly, for
MSSA infective endocarditis (IE), empirical therapy with
vancomycin was associated with signiﬁcantly greater infec-
tion-related mortality than treatment with b-lactams [18],
and complication rates during therapy and durations of
intensive-care unit stay were signiﬁcantly higher with vanco-
mycin [19]. In addition, there is mounting evidence that the
value of the MIC of vancomycin within the susceptible range
(£2.0 mg/L) inﬂuences clinical outcome, potentially rendering
adequate therapy relatively inappropriate. For example,
Sakoulas et al. [20] found that a vancomycin MIC of
1.0–2.0 mg/L was associated with signiﬁcantly lower vanco-
mycin treatment success rates in MRSA bacteraemia than a
vancomycin MIC of 0.5 mg/mL (55.6% vs. 9.5%; p ¼0.01).
Similarly, Lodise et al. [21] determined that vancomycin
MICs of ‡1.5 mg/L were associated with a 2.4-fold increase
in treatment failure as compared with vancomycin MICs of
£1.0 mg/L (36.4% vs. 15.4%; p ¼0.049). Other data suggest
that increased doses of vancomycin may not compensate
for elevated MICs [22], and high vancomycin doses (4 g)
are associated with an increased risk of nephrotoxicity [23].
Choosing the most appropriate empirical therapy for a
patient is critical in reducing the risk of morbidity and mor-
tality [3,12]. The likelihood of patients receiving inadequate
empirical therapy increases with the increasing prevalence of
infections caused by antimicrobial-resistant bacteria. Local
epidemiology and resistance rates should therefore be taken
into consideration [6]. Several studies have demonstrated
that the administration of inadequate empirical antimicrobial
therapy (Fig. 1) [5,7–10] and, furthermore, inappropriate
empirical therapy (Fig. 2) [4,11] signiﬁcantly increase the rate
of mortality in infections such as bloodstream infections,
MRSA sterile site infections, nosocomial pneumonia, and ven-
tilator-associated pneumonia. In addition, delaying therapy
for S. aureus bacteraemia has been shown to increase the
risk of mortality and the overall length of hospitalization
[12]; early administration of appropriate therapy in S. aureus
infections is key to reducing these risks. Identiﬁcation of bac-
teria from patient isolates can take up to 3 days from pre-
sentation of the patient to the healthcare facility, with the
potential for contamination of samples by S. aureus colonizing
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FIG. 1. The impact of inadequate therapy on mortality rates in bloodstream infections, ventilator-associated pneumonia, nosocomial pneumonia
and methicillin-resistant Staphylococcus aureus (MRSA) sterile site infections [5,7–10].
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the skin [24]. Delaying therapy for this length of time is often
not an option, so an empirical therapy is required to treat
the suspected infection.
Case Study I—Infective Endocarditis (IE)
IE is a common complication among intravenous drug users
(IVDUs), with an incidence of 1–5% per year, and is respon-
sible for 5–10% of the overall death rate in these patients
[25]. The tricuspid valve (right-sided) is most frequently
affected in IVDUs [26,27]; however, both left-sided and
right-sided valves are involved in approximately 5–10% of
cases [28]. This predisposition to right-sided IE in IVDUs is
thought to be attributable to the injection of bacterial loads,
either as part of the particulate matter or as a contaminant,
directly into the venous system [28]. The most frequent
causes of bacterial IE are Gram-positive organisms, with
S. aureus being the bacterial species that is most often iso-
lated [29,30]. Worldwide, the S. aureus isolates causing IE in
IVDUs are usually methicillin-susceptible [28]. IE caused by
MRSA is associated with a higher rate of persistent bacter-
aemia than the infection caused by MSSA, and has a non-sig-
niﬁcant trend towards higher mortality rates [30]. Here, I
report on the case of a patient with right-sided IE who was
successfully treated with empirical daptomycin.
A 32-year-old male with a history of intravenous drug use,
who had been suffering with fever and chills for 3 days, was
admitted to hospital. He had been admitted previously on
multiple occasions for trauma, and had received a gunshot
wound to the abdomen 2 months earlier, which was compli-
cated by an MRSA catheter-related bloodstream infection.
However, prior antimicrobial therapy was not documented.
Clinical examination of the patient revealed tachycardia and a
II/VI systolic ejection murmur; the patient’s abdomen was
benign, and his chest was clear to auscultation. He presented
with a temperature of 40C, respiratory and heart rates of
24 breaths/min and 108 beats/min, respectively, blood pres-
sure of 104/72 mmHg, and right atrial O2 saturation of 99%.
No Osler’s nodes, splinter haemorrhages or Janeway’s
lesions were present. Laboratory results revealed an elevated
white blood cell count (15.4 · 109/L) and anaemia (haemo-
globin 10.4 g/dL, haematocrit 32%); blood urea nitrogen and
creatinine were within normal ranges.
Empirical treatment with daptomycin (6 mg/kg every 24 h)
and piperacillin–tazobactam was started (4.5 g every 6 h)
after admission and initial diagnostic studies. Blood cultures
drawn on admission grew Gram-positive cocci in clusters,
which were later (48 h after admission) identiﬁed as MRSA
with a vancomycin MIC of 2 mg/L and a daptomycin MIC of
0.5 mg/L. In addition, the organism was susceptible to
tetracyclines, trimethoprim–sulphamethoxazole and rifampin,
and resistant to quinolones and clindamycin. Transthoracic
echocardiography ﬁndings were normal, but transoesophageal
echocardiography showed an 8-mm vegetation on the tricus-
pid valve. Daptomycin treatment was continued, but
piperacillin–tazobactam was discontinued following a 2-day
treatment duration. Blood cultures were negative for growth
on the third day of antimicrobial therapy. The patient was
transferred to a chronic-care facility to complete a 6-week
course of daptomycin, but signed out, against medical advice,
after a total of 3 weeks of therapy, and was lost to follow-up.
His condition on discharge was good.
This patient was suffering from S. aureus bacteraemia with
concurrent right-sided IE, and the bacteraemia resolved after
administration of an appropriate empirical treatment regi-
men. In IVDUs, when treating endocarditis caused by S. aur-
eus, it has been shown that infection-related mortality is
reduced if an appropriate empirical regimen is chosen
(Fig. 3) [18]. For this patient, it was unknown initially
whether the infecting organism was MSSA or MRSA; there-
fore, the best possible option was therapy that covered
both. In this case, administering an antimicrobial ineffective
against MRSA would have delayed the receipt of adequate
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FIG. 2. The impact of inappropriate therapy on mortality rates in
bloodstream infections [4,11]. As deﬁned by relevant investigators:
therapy was appropriate if it was started within 2 days of the ﬁrst
positive blood culture, if the infecting microorganism was subse-
quently found to be susceptible in vitro to the drug administered, and
if the antimicrobial was given intravenously [4]; therapy was appro-
priate if the initial antimicrobials, which were administered within
24 h after the acquisition of a blood culture sample, included at least
one antimicrobial that was active in vitro and when the dosage and
route of administration were consistent with current medical stan-
dards [11].
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treatment, increasing the patient’s risk of mortality. In addi-
tion, the high vancomycin MIC for the MRSA isolate indicates
an elevated likelihood that vancomycin would not have been
an effective therapy [20–22,31–34], and may therefore not
have been the most appropriate option in this case.
Empirical monotherapy options that provide coverage
against both MSSA and MRSA are limited. Daptomycin is one
such agent, having been shown to be as effective as compara-
tors for treating right-sided IE caused by either MSSA or
MRSA in a phase III trial [35]. Another property of daptomy-
cin that makes it appropriate for the treatment of this
patient population is its rapid bactericidal activity, which is
considered to be important for treatment efﬁcacy in serious
infections such as IE [36,37]. Daptomycin demonstrates
concentration-dependent killing in in vitro models of IE, with
a more rapid rate of bacterial killing than vancomycin [38],
as well as against high-dose inocula and organisms in the
stationary growth phase [39,40]. The mechanism of action of
daptomycin, i.e. rapidly bactericidal but not bacteriolytic [41],
is another potential beneﬁt of this agent, as its use should
not lead to any major clinical symptoms associated with the
rapid lysis of bacteria within the body [42].
Case Study 2—Community-Acquired
MRSA (CA-MRSA)
CA-MRSA is deﬁned as an MRSA infection acquired outside
of healthcare-associated settings [43]. Several risk factors
have been identiﬁed for the development of infections
caused by CA-MRSA, including participation in contact
sports, residence in correctional facilities, and attendance at
day-care and other institutional centres [44]. Military recruits
and homosexual men are also at particular risk for
CA-MRSA infection [44]. Although risk factors are useful for
assessing the risk of infection with antimicrobial-resistant
Gram-negative bacteria, they are much less predictive of
infection with MRSA in the USA, because of the high preva-
lence of this strain in community-acquired infections [45]. A
recent study has shown that empirical treatment of
CA-MRSA complicated skin and soft tissue infections
(cSSTIs), guided by an algorithm that promotes the use of
antimicrobials that are active in vitro against CA-MRSA, is
associated with improved clinical outcomes as compared
with administering empirical therapy that is less effective
against MRSA [46]. Here, I report the case of a patient with
a community-acquired cSSTI and concurrent bacteraemia
who was successfully treated empirically with daptomycin.
A 30-year-old man, released from a state correctional
facility 14 months earlier, was admitted to hospital with fever,
chills and facial cellulitis. The patient presented with swelling
and redness of the lips and left side of the face (with no peri-
orbital oedema or drainage), a temperature of 39.4C, a heart
rate of 110 beats/min, a respiratory rate of 20 breaths/min,
and a blood pressure of 128/82 mmHg. Blood analyses
revealed that the patient was human imunodeﬁciency virus-
negative. Treatment was initially started with ampicillin–sul-
bactam (3.0 g intravenously every 6 h). However, cultures
from blood drawn on admission were shown to be positive
for Gram-positive cocci, so treatment was switched after
1 day to daptomycin (6 mg/kg every 24 h) to provide cover-
age against both MSSA and MRSA. Blood cultures were later
shown to be positive for MRSA that was susceptible to
vancomycin (MIC 0.5 mg/L), erythromycin (MIC 2 mg/L),
clindamycin (MIC <2 mg/L), levoﬂoxacin (MIC <1 mg/L),
rifampin (MIC £1 mg/L), tetracycline (MIC £2 mg/L), trimeth-
oprim–sulphamethoxazole (MIC £2/38 mg/L) and daptomycin
(MIC 0.5 mg/L), according to CLSI breakpoints [47]. Transo-
esophageal echocardiography ﬁndings were negative for vege-
tations, and a computerized tomography scan of the facial
bones was negative for abscess, osteomyelitis and sinusitis.
The patient received daptomycin treatment for 14 days;
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lin-susceptible Staphylococcus aureus endocarditis [18].
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repeat blood cultures after this time were negative, and the
facial cellulitis resolved.
The emergence and spread of CA-MRSA in the USA has
reduced the utility of traditional risk factors for identifying
patients with MRSA. Therefore, in such a scenario, it may be
appropriate to presume that any serious infection potentially
caused by staphylococci could be MRSA until culture results
are available. In many European countries, MRSA rates [1]
are such that coverage against MRSA with empirical therapy
should be strongly considered for hospital-acquired staphylo-
coccal infections. However, CA-MRSA has also been docu-
mented in several European countries [48], raising the
possibility that Europe may follow a trend similar to that in
the USA. In the future, even community-acquired staphylo-
coccal infections may need to be treated empirically as
MRSA. Daptomycin has been shown to be rapidly bacterici-
dal in vitro against CA-MRSA strains, with 99% of bacteria
being killed in less than 2 h at 4 · MIC [49], and has also
been shown to be as effective as comparator therapies for
treating cSSTIs caused by Gram-positive bacteria, including
MSSA, MRSA and enterococci [50]. These data indicate that
daptomycin is an effective choice for the empirical treatment
of suspected Gram-positive cSSTIs.
Summary
Choosing the most appropriate empirical therapy is critical
for obtaining the best patient outcomes. However, determi-
nation of the optimal treatment regimen is often complicated
by the possibility of reduced antimicrobial sensitivity of the
infecting bacterial strains. Treatment of infections caused by
S. aureus can be particularly complex because of varying
prevalences of MRSA, and the consequences of increased
mortality and hospital length of stay associated with the use
of inappropriate empirical therapies. The optimal empirical
coverage against Gram-positive pathogens should include
agents that are effective against antimicrobial-susceptible and
antimicrobial-resistant strains. Because of its rapid bacterici-
dal activity and proven clinical efﬁcacy in infections caused
by Gram-positive bacteria, including antimicrobial-resistant
strains such as MRSA, daptomycin may be an appropriate
option for the empirical treatment of serious Gram-positive
infections, independent of methicillin susceptibility [35,50].
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